Ftse Mib
34.134,14
-0,08%
DAX
19.909,14
-0,25%
S&P 500
5.970,84
0,00%
NASDAQ
19.722,03
0,00%
Bitcoin
92.754,47
-0,82%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX IGC Pharma Inc (IGC) IGC Pharma Inc (IGC) Notizie

IGC

IGC Pharma (IGC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:IGC
DataOraFonteTitoloSimboloCompagnia
25/11/202414:30Business WireIGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
12/11/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
27/09/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
27/09/202422:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/09/202414:00Business WireIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
04/09/202414:00Business WireIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
27/08/202401:00Business WireIGC Announces Results of its 2024 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
22/08/202415:00Business WireIGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
20/08/202414:00Business WireIGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistAMEX:IGCIGC Pharma Inc
14/08/202422:23Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:IGCIGC Pharma Inc
09/08/202403:30Business WireIGC Pharma Reports First Quarter Fiscal 2025 ResultsAMEX:IGCIGC Pharma Inc
18/07/202415:00Business WireIGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetAMEX:IGCIGC Pharma Inc
09/07/202420:17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:IGCIGC Pharma Inc
09/07/202415:10Business WirePreclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety ProfileAMEX:IGCIGC Pharma Inc
08/07/202422:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
25/06/202415:00Business WireIGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
25/06/202401:30Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2024AMEX:IGCIGC Pharma Inc
18/06/202415:00Business WireIGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsAMEX:IGCIGC Pharma Inc
10/06/202415:00Business WireIGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 TetrahydrocannabinolAMEX:IGCIGC Pharma Inc
28/05/202415:00Business WireIGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1AMEX:IGCIGC Pharma Inc
22/05/202403:20Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:IGCIGC Pharma Inc
21/05/202420:00Business WireIGC Pharma to Attend BIO International Convention 2024AMEX:IGCIGC Pharma Inc
14/05/202403:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
16/04/202413:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202415:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202420:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202416:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202412:00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
12/03/202420:00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
28/02/202419:00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:IGC

La tua Cronologia

TSXV
ERA
Elcora Advanced Materials
LSE
52RS
Gforth 18-1 A1s
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network